News in Brief

Published: 1-Mar-2003


  • Bristol-Myers Squibb has agreed to pay US$670m (€626m) to settle numerous lawsuits after it was accused of using illegal tactics to keep lower-priced versions of its medicines, cancer-fighting Taxol and the anti-anxiety drug BuSpar, out of the market for many months. Both drugs are now available as generic medicines.

  • The EU has initiated formal talks ; the first stage of disputes proceedings at the World Trade Organisation ; over import restrictions imposed by the Indian government on a range or products including penicillin, its salts, and derivatives, rifampicin, streptomycins or their derivatives, and first aid boxes or kits.

  • The European Agency for the Evaluation of Medicinal Products (EMEA) has announced that the EU marketing authorisation for hepatitis B treatment Hepacare has been withdrawn by the European Commission. The decision followed manufacturer Celltech Pharmaceuticals' commercial decision to abandon plans to sell the medicine. Alternative vaccines are available in Europe.

  • An EU-funded research project has identified four strains of lactobacilli that could help treat intestinal inflammations and infections. The aim of the Deprohealth scheme, which has received €1.4m ($1.5m) in Brussels money; is to develop oral probiotic bacteria vaccines to counter conditions such as rotavirus, which causes infant diarrhoea, and Crohn's disease. Participating researchers from France, Italy, Belgium, Spain, the UK and Australia have had to identify strains that not only prevented inflammation, but also could withstand human digestive acids.

  • A US federal judge has ruled that an approval letter with a delayed effective date given by the FDA should be considered merely a tentative approval and does not give a manufacturer the legal right to begin marketing a medicine. The judge was ruling against Barr Laboratories' bid to market a generic version of tamoxifen tablets, which the company had expected to release last August. He quashed a bid by Barr to overturn FDA restrictions on selling a product ahead of its release. The FDA had stressed that Barr should wait until the original patent currently held by AstraZeneca had expired.
    See more

    • You may also like

    Packaging

    Parenteral Drug Association to host innovation in sustainable packaging workshop at Pharmapack 2026

    Read more
    The Parenteral Drug Association (PDA) will host a half-day workshop titled “PDA Innovation in Sustainable Packaging Workshop 2026” on Day One of Pharmapack Europe in Paris

    Trending Articles

    1. Ingenza debuts Bacillus protein production system alternative to E. coli The Scottish CRDMO's new GenXpress Bacillus technology offers a highly productive alternative to the traditional E. coli expression systems that is free from endotoxins and antibiotic resistance markers
    2. IMA Life-Sharp Sterile Manufacturing partnership strengthened with aseptic technology facility Sharp's expanded facility in Massachusetts will include the installation of a fully automated IMA Life isolated filling line for Ready-To-Use (RTU) vials, addressing demand for US-based aseptic fill-finish services
    3. FDA and EMA issue guiding principles for AI in drug development The set of ten principles gives broad guidance on AI use in evidence generation and monitoring across all phases of a medicine, from early research and clinical trials to manufacturing and safety monitoring
    4. Enara Bio expands Boehringer Ingelheim partnership as DARKFOX programme moves toward the clinic Enara Bio has entered 2026 with renewed momentum after Boehringer Ingelheim licensed additional Dark Antigen targets under their oncology collaboration. The company is also continuing to expand its EDAPT discovery platform
    5. You need to be a subscriber to read this article.
      Click here to find out more.
      Miniaturisation in medtech: mechanical factors that influence product success Medical devices are becoming smaller, lighter and more portable. From handheld diagnostic tools to wearable infusion pumps and compact surgical instruments, reduced size is now a defining feature of many new medtech products

    Upcoming event

    Pharmapack

    21–22 January 2026 | Exhibition | Paris, France     See all

    You may also like

    Packaging

    Parenteral Drug Association to host innovation in sustainable packaging workshop at Pharmapack 2026

    The Parenteral Drug Association (PDA) will host a half-day workshop titled “PDA Innovation in Sustainable Packaging Workshop 2026” on Day One of Pharmapack Europe in Paris
    Manufacturing

    OMRON introduces new high-payload collaborative robots and TMflow software upgrade

    OMRON unveils advanced collaborative robots and upgraded TMflow software to boost manufacturing flexibility and productivity
    Packaging

    ACG Packaging Materials launches SuperPod to set a new benchmark for cold-form blister design

    ACG Packaging Materials, which manufactures the world’s widest range of film and foil blister and lidding products, has launched its breakthrough cold-form blister technology: SuperPod
    Manufacturing

    Sharp Services invests more than €20m to expand injectables packaging capacity at its European facilities

    Expansion includes significant cold chain warehouse capacity to support injectable formats
    Ingredients

    SÜDPACK Medica showcases recyclable blister and medical packaging innovations at PharmaPack 2026

    From recyclable PP blisters to cleanroom-manufactured pouch solutions, SÜDPACK Medica highlights sustainability and performance in pharma packaging
    Manufacturing

    Key drivers behind the rise of microsphere drug delivery systems

    Microspheres shift drug delivery from broad distribution to precise targeting. These systems improve therapeutic consistency, lower systemic exposure, and adapt to complex treatment regimens. Their growth reflects progress in polymer science, pharmacokinetics, and the push for more individualised care in clinical settings. Let’s explore some of the key drivers behind the rise of microsphere drug delivery systems and look ahead to predict future growth trends
    Manufacturing

    Inside the shift toward greener, faster, Smarter drug manufacturing

    Dave Henderson, Ph.D, MBA, Head of R&D Labs at Asymchem explores the pharmaceutical manufacturing landscape and the challenges CDMOs must address to remain competitive in this shifting market
    Subscribe now